[
  {
    "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.txt",
    "perturbation": [
      {
        "type": "Omissions - Omission Legal Contradiction",
        "original_text": "2.8 MD Anderson and Adaptimmune shall comply with all applicable federal, state and local laws pertaining to confidentiality, consent and disclosure of all information or records obtained and reviewed in the course of the Study, and shall permit access to such information or records only as authorized by a relevant Study subject, the IRB, and as authorized by law. Each Party agrees to comply with all provisions of the Health Insurance Portability and Accountability Act (\"HIPAA\") regulations (45 C.F.R.",
        "changed_text": "2.8 MD Anderson and Adaptimmune shall comply with all applicable federal, state and local laws pertaining to confidentiality and disclosure of all information or records obtained and reviewed in the course of the Study, and shall permit access to such information or records only as authorized by a relevant Study subject, the IRB, and as authorized by law. Each Party agrees to comply with provisions of state laws regarding patient information.",
        "explanation": "The omission of 'consent' and the specific reference to HIPAA (Health Insurance Portability and Accountability Act) weakens the protection of patient data. The removal of direct HIPAA compliance is a legal risk since clinical studies in the US must adhere to it when handling patient health information. Replacing HIPAA with a general reference to state laws reduces the obligation.",
        "contradicted_law": "Health Insurance Portability and Accountability Act (HIPAA)",
        "law_citation": "45 C.F.R. Parts 160 and 164",
        "law_url": "https://www.hhs.gov/hipaa/for-professionals/privacy/index.html",
        "law_explanation": "HIPAA mandates specific requirements for the use and disclosure of protected health information. By removing the explicit reference to HIPAA compliance, the modified text introduces ambiguity regarding the required level of protection for patient data, making it potentially non-compliant.",
        "location": "Section 2.8",
        "scraped_snippet": "Privacy | HHS.gov Skip to main content Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you\u2019ve safely connected to the .gov website. Share sensitive information only on official, secure websites. Navigate to: The HIPAA Privacy Rule The HIPAA Privacy Rule establishes national standards to protect individuals' medical records and other individually identifiable health information (collectively defined as \u201cprotected health information\u201d) and applies to health plans, health care clearinghouses, and those health care providers that conduct certain health care transactions electronically. The Rule requires appropriate safeguards to protect the privacy of protected health information and sets limits and conditions on the uses and disclosures that may be made of such information without an individual\u2019s authorization. The Rule also gives individuals rights over their protected health information, including rights to examine and obtain a copy of their health records, to direct a covered entity to transmit to a third party an electronic copy of their protected health information in an electronic health record, and to request corrections. The Privacy Rule is located at 45 CFR Part 160 and Subparts A and E of Part 164 . Click here to view the combined regulation text of all HIPAA Administrative Simplification Regulations found at 45 CFR 160, 162, and 164. Privacy Rule History April 26, 2024 - HIPAA Privacy Rule to Support Reproductive Health Care Privacy - Final Rule April 17, 2023 - HIPAA Privacy Rule to Support Reproductive Health Care Privacy - Proposed Rule March 10, 2021 - Extension of Comment Period for Modifications to the HIPAA Privacy Rule to Support, and Remove Barriers to, Coordinated Care and Individual Engagement \u2013 Proposed Rule January 21, 2021 - Modifications to the HIPAA Privacy Rule to Empower Patients, Improve Coordinated Care, and Reduce Regulatory Burdens - Proposed Rule December 14, 2018 - Modifying the HIPAA Rules to Improve Coordinated Care - Request for Information January 6, 2016 - HIPAA Privacy Rule and the National Instant Criminal Background Check System (NICS) - Final Rule February 6, 2014 - Patients' Access to Test Reports Under the HIPAA Privacy Rule and the Clinical Laboratory Improvement Amendments of 1988 (CLIA) Program - Final Rule January 7, 2014 - HIPAA Privacy Rule and NICS - Proposed Rule April 23, 2013 - HIPAA Privacy Rule and NICS - Advance Notice of Proposed Rulemaking January 25, 2013 - Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules under the Health Information Technology for Economic and Clinical Health (HITECH) Act and the Genetic Information Nondiscrimination Act, and Other Modifications - Final Rule (The \"Omnibus HIPAA Final Rule\") September 14, 2011 - Patients' Access to Test Reports Under the HIPAA Privacy Rule and CLIA Program - Proposed Rule May 31, 2011 - HIPAA Privacy Rule Accounting of Disclosures Under the HITECH Act - Proposed Rule July 14, 2010 - Modifications to the HIPAA Privacy, Security, and Enforcement Rules under the HITECH Act - Proposed Rule May 3, 2010 - HIPAA Privacy Rule Accounting of Disclosures Under the HITECH Act - Request for Information October 7, 2009 - HIPAA Privacy Rule; Modifications Under the Genetic Information Nondiscrimination Act - Proposed Rule August 14, 2002 - Modifications to the HIPAA Privacy Rule - Final Rule ( PDF ) March 27, 2002 - Modifications to the HIPAA Privacy Rule - Proposed Rule ( PDF ) February 28, 2001 - Request for Comments on December 28, 2000, Final HIPAA Privacy Rule ( PDF ) February 26, 2001 - Correction of Effective and Compliance Dates of the Final HIPAA Privacy Rule ( PDF ) December 29, 2000 - Technical Corrections to the Final HIPAA Privacy Rule ( PDF ) December 28, 2000 - HIPAA Privacy Rule - Final Rule ( PDF ) November 3, 1999 - HIPAA Privacy Rule ",
        "contradiction_score": 0.7,
        "justification": "The original contract text explicitly states compliance with HIPAA regulations (45 C.F.R.), a federal law establishing national standards to protect individuals' medical records. The changed text removes the specific reference to HIPAA compliance and replaces it with a general statement about complying with state laws regarding patient information. The scraped law snippet clearly defines HIPAA as setting national standards for the protection of health information, requiring safeguards and setting limits on the use and disclosure of such information. By removing the explicit HIPAA compliance requirement, the changed text introduces ambiguity and potentially lowers the standard of protection for patient data, creating a legal risk. While state laws may also address patient data protection, they may not be equivalent to or as comprehensive as HIPAA. The removal of 'consent' also weakens patient data protection, further deviating from the stringent safeguards mandated by HIPAA."
      },
      {
        "type": "Omissions - Omission Legal Contradiction",
        "original_text": "10.1 Adaptimmune shall assume responsibility for reasonable medical expenses incurred by a Study subject for reasonable and necessary treatment if the Study subject experiences an illness, adverse event or injury that is a result of the Study Drug or any procedure required by the Protocol that the subject would not have undergone were it not for such Study subject's participation in the Study. Adaptimmune shall not be responsible for expenses to the extent that they are due to pre-existing medical conditions, underlying disease, or the negligence or intentional misconduct or due to breach of this Agreement by MD Anderson or Principal Investigator. Adaptimmune shall have no obligation to make any payments for any Study patient that is not eligible for inclusion in any Protocol. Any payments for such medical expenses shall be subject to Adaptimmune receiving relevant documentation supporting the claim for such medical expenses.",
        "changed_text": "10.1 Adaptimmune may consider assuming responsibility for medical expenses incurred by a Study subject for treatment if the Study subject experiences an illness or injury that is a result of the Study Drug or any procedure required by the Protocol. Adaptimmune shall not be responsible for expenses to the extent that they are due to pre-existing medical conditions or underlying disease. Any payments for medical expenses are subject to Adaptimmune receiving documentation supporting the claim.",
        "explanation": "By changing 'shall assume responsibility' to 'may consider assuming responsibility,' the contract weakens Adaptimmune's obligation to cover medical expenses for subjects injured during the study. Removing 'reasonable and necessary treatment', 'adverse event', 'negligence or intentional misconduct', and the protocol clause allows Adaptimmune to potentially deny coverage in cases where it would otherwise be required. This violates basic protections for research participants.",
        "contradicted_law": "21 CFR Part 50 - Protection of Human Subjects",
        "law_citation": "21 CFR Part 50",
        "law_url": "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50",
        "law_explanation": "21 CFR Part 50 outlines requirements for informed consent and protection of human subjects in clinical trials. By weakening the financial responsibility for medical expenses resulting from the study, it introduces a situation where subjects may not receive appropriate care, potentially violating the ethical standards required by this regulation.",
        "location": "Section 10.1",
        "scraped_snippet": "eCFR :: 21 CFR Part 50 -- Protection of Human Subjects Site Feedback You are using an unsupported browser \u00d7 You are using an unsupported browser. This web site is designed for the current versions of Microsoft Edge, Google Chrome, Mozilla Firefox, or Safari. \u00d7 Site Feedback The Office of the Federal Register publishes documents on behalf of Federal agencies but does not have any authority over their programs. We recommend you directly contact the agency associated with the content in question. If you have comments or suggestions on how to improve the www.ecfr.gov website or have questions about using www.ecfr.gov, please choose the 'Website Feedback' button below. Website Feedback If you would like to comment on the current content, please use the 'Content Feedback' button below for instructions on contacting the issuing agency Content Feedback If you have questions for the Agency that issued the current document please contact the agency directly. \u00d7 Website Feedback * Your Name * Email Attachment * How can we help you? * I am requesting technical help or providing website feedback This contact form is only for website help or website suggestions. If you have questions or comments regarding a published document please contact the publishing agency. Comments or questions about document content can not be answered by OFR staff. Please do not provide confidential information or personal data. Browse Titles Agencies Incorporation by Reference Recent Updates Search Recent Changes Corrections Reader Aids Reader Aids Home Using the eCFR Point-in-Time System Understanding the eCFR Government Policy and OFR Procedures Developer Resources My eCFR My Subscriptions Sign Out Sign In / Sign Up Sign In / Sign Up Hi, Sign Out eCFR The Electronic Code of Federal Regulations Enhanced Content :: FR Reference Enhanced content is provided to the user to provide additional context. Enhanced Content :: FR Reference Title 21 This content is from the eCFR and is authoritative but unofficial. Displaying title 21, up to date as of 4/10/2025. Title 21 was last amended 3/31/2025. view historical versions A drafting site is available for use when drafting amendatory language switch to drafting site Navigate by entering citations or phrases (eg: 1 CFR 1.1 49 CFR 172.101 Organization and Purpose 1/1.1 Regulation Y FAR ). Choosing an item from citations and headings will bring you directly to the content. Choosing an item from full text search results will bring you to those results. Pressing enter in the search box will also bring you to search results. Background and more details are available in the Search & Navigation guide. Title 21 \u2014Food and Drugs Chapter I \u2014Food and Drug Administration, Department of Health and Human Services Subchapter A \u2014General Part 50 Previous Next Top Table of Contents Enhanced Content - Table of Contents Part 50 Protection of Human Subjects 50.1 \u2013 50.56 Subpart A General Provisions 50.1 \u2013 50.3 \u00a7 50.1 Scope. \u00a7 50.3 Definitions. Subpart B Informed Consent of Human Subjects 50.20 \u2013 50.27 \u00a7 50.20 General requirements for informed consent. \u00a7 50.22 Exception from informed consent requirements for minimal risk clinical investigations. \u00a7 50.23 Exception from general requirements. \u00a7 50.24 Exception from informed consent requirements for emergency research. \u00a7 50.25 Elements of informed consent. \u00a7 50.27 Documentation of informed consent. Subpart C [Reserved] Subpart D Additional Safeguards for Children in Clinical Investigations 50.50 \u2013 50.56 \u00a7 50.50 IRB duties. \u00a7 50.51 Clinical investigations not involving greater than minimal risk. \u00a7 50.52 Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects. \u00a7 50.53 Clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects' disorder or condition. \u00a7 50.54 Clinical investigations not otherwise approvable that p",
        "contradiction_score": 0.7,
        "justification": "The original contract language, 'Adaptimmune shall assume responsibility,' created a clear obligation for Adaptimmune to cover reasonable medical expenses for study-related injuries. The changed text weakens this obligation by stating Adaptimmune 'may consider assuming responsibility.' This introduces ambiguity and allows Adaptimmune to potentially deny coverage. The Law Explanation points to 21 CFR Part 50, which outlines requirements for informed consent and protection of human subjects in clinical trials. While the scraped snippet of 21 CFR Part 50 provided does not explicitly mention financial responsibility for medical expenses, the Perturbation Explanation suggests this weakening of financial responsibility potentially violates ethical standards within the regulation concerning subject protection, as patients may not receive appropriate care if the company decides not to assume responsibility. Although the scraped snippet doesn't directly address financial responsibility, the principle of protecting human subjects in clinical trials, implied by 21 CFR Part 50, is undermined by the change, thus the contradiction score of 0.7."
      },
      {
        "type": "Omissions - Omission Legal Contradiction",
        "original_text": "15.1 Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE RESULTS OF ANY STUDY OR THE STUDY DRUG, OR OF THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH DATA, RESULTS OR STUDY DRUG. NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT OR CONSEQUENTIAL DAMAGES SUFFERED BY THE OTHER PARTY AS A RESULT OF PERFORMANCE OF ANY STUDY UNDER THIS AGREEMENT. ADAPTIMMUNE REPRESENTS AND WARRANTS THAT EACH STUDY DRUG HEREUNDER SHALL HAVE BEEN MANUFACTURED IN ACCORDANCE WITH CURRENT GOOD MANUFACTURING PRACTICES IN THE UNITED STATES AND THAT AS AT THE EFFECTIVE DATE OF THIS AGREEMENT IT HAS NOT RECEIVED ANY CLAIM THAT USE OF ANY STUDY DRUG IN THE PERFORMANCE OF A STUDY WOULD INFRINGE THE RIGHTS OF ANY THIRD PARTY. ADAPTIMMUNE REPRESENTS THAT AS AT THE EFFECTIVE DATE TO ITS KNOWLEDGE THERE ARE NO KNOWN DEFECTS IN ANY STUDY DRUG; ADAPTIMMUNE UNDERSTANDS AND ACKNOWLEDGES THAT THE DEVELOPMENT AND DISSEMINATION OF SCIENTIFIC KNOWLEDGE IS A FUNDAMENTAL COMPONENT OF MD ANDERSON'S MISSION, AND THAT MD ANDERSON MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES WITH RESPECT TO ANY SPECIFIC RESULTS OF THE STUDIES.",
        "changed_text": "15.1 Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE RESULTS OF ANY STUDY OR THE STUDY DRUG, OR OF THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH DATA, RESULTS OR STUDY DRUG. NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT OR CONSEQUENTIAL DAMAGES SUFFERED BY THE OTHER PARTY AS A RESULT OF PERFORMANCE OF ANY STUDY UNDER THIS AGREEMENT. ADAPTIMMUNE UNDERSTANDS AND ACKNOWLEDGES THAT THE DEVELOPMENT AND DISSEMINATION OF SCIENTIFIC KNOWLEDGE IS A FUNDAMENTAL COMPONENT OF MD ANDERSON'S MISSION, AND THAT MD ANDERSON MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES WITH RESPECT TO ANY SPECIFIC RESULTS OF THE STUDIES.",
        "explanation": "The omission removes Adaptimmune's warranties regarding the manufacturing and third-party rights related to the Study Drug. This creates a legal risk by potentially exposing MD Anderson to liability if the drug is not manufactured according to standards or if it infringes on another party's rights. This also affects patient safety, as the explicit assurance of good manufacturing practices is removed.",
        "contradicted_law": "21 U.S. Code \u00a7 351 - Adulterated drugs and devices",
        "law_citation": "21 U.S. Code \u00a7 351",
        "law_url": "https://www.law.cornell.edu/topn/adulterated%20drugs",
        "law_explanation": "21 U.S. Code \u00a7 351 defines what constitutes an adulterated drug. By removing the warranty that the drug is manufactured according to Good Manufacturing Practices, the contract weakens the assurance that the drug is not adulterated, thereby potentially exposing study participants and MD Anderson to legal and health risks associated with using a non-compliant drug.",
        "location": "Section 15.1",
        "scraped_snippet": null,
        "contradiction_score": 0.6,
        "justification": "The original contract text includes Adaptimmune's warranty that the study drug was manufactured in accordance with current Good Manufacturing Practices (cGMP) in the United States. The changed text omits this warranty. The Law Explanation states that removing the warranty weakens the assurance that the drug is not adulterated under 21 U.S. Code \u00a7 351, potentially exposing study participants and MD Anderson to legal and health risks. Although a specific law snippet wasn't provided to directly support the illegality of this omission, the Law Explanation and Perturbation Explanation together create a moderately strong contradiction because the omission removes a significant assurance regarding drug safety and compliance, which could implicate risks related to adulteration as highlighted by the LLM's generated law explanation."
      }
    ]
  }
]